Lynparza Olaparib: Phase I started

Cancer Research UK began the open-label, dose-escalation, U.K. Phase I PIONEER trial to evaluate once- or twice-daily oral Lynparza in combination with Xeloda capecitabine and radiotherapy in up to ...